Investment Rating - The report indicates a positive long-term outlook for the weight loss drug industry, particularly focusing on GLP-1 medications, suggesting to maintain a long-term focus on the weight loss drug industry chain [3]. Core Insights - The importance of weight loss drugs has been reaffirmed, with the WHO developing new guidelines for obesity prevention and treatment, expected to be finalized by August or September 2025. This is anticipated to standardize the use of GLP-1 drugs, enhancing their application in weight management [3][13]. - The FDA has expanded its inspections of overseas manufacturing facilities, which is expected to benefit leading CDMO companies in China that have established quality systems meeting global standards [3][16]. - The pharmaceutical and biotechnology sector saw a weekly increase of 1.5%, underperforming compared to the overall A-share market and the CSI 300 index, with offline pharmacies and medical devices showing the highest gains [3][8]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.5% from April 28 to May 9, lagging behind the overall A-share market (2.32%) and the CSI 300 index (1.56%). Offline pharmacies (5.64%), medical devices (4.49%), and medical R&D outsourcing (2.78%) led the gains, while vaccines (-0.45%), blood products (-0.43%), and in vitro diagnostics (-0.17%) saw declines [3][8]. Industry News and Key Company Announcements - Significant events include the WHO's ongoing development of obesity guidelines, which will clarify the clinical applications of GLP-1 drugs [3][13]. - The FDA's announcement on May 6 regarding expanded inspections of foreign manufacturers aims to ensure equal regulatory oversight for foreign companies [3][16]. - Notable company announcements include the approval of new indications for various drugs and the financial performance of companies like BeiGene, which reported a 50.2% year-on-year revenue increase in Q1 [3][12][17].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on the weight-loss drug industry chain due to the increasing importance of weight-loss medications [3]. Core Insights - The importance of weight-loss drugs has been reaffirmed, with the WHO developing new guidelines for obesity prevention and treatment, expected to be finalized by August or September 2025. This includes the use of GLP-1 medications for adult obesity management, which may standardize their application and increase their usage in weight-loss populations [3][13]. - The FDA has expanded surprise inspections of overseas manufacturing facilities, particularly in India and China, to ensure foreign companies meet the same regulatory standards as U.S. companies. This is expected to benefit leading CDMO companies in China that have established quality systems compliant with global standards [3][16]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.5% from April 28 to May 9, underperforming the Wind All A index (2.32%) and the CSI 300 index (1.56%). The best-performing segments included offline pharmacies (5.64%), medical devices (4.49%), and medical research outsourcing (2.78%), while vaccines (-0.45%), blood products (-0.43%), and in vitro diagnostics (-0.17%) lagged [3][8]. - Notable individual stock performances included Changshan Pharmaceutical (26.28%) and Haichuang Pharmaceutical (25.85%), both linked to the weight-loss drug concept [3][11]. Industry News and Key Company Announcements - On May 9, the NMPA approved a new indication for Hansoh Pharmaceutical's Amivantamab, targeting specific mutations in non-small cell lung cancer [12]. - The report highlights significant developments in the industry, including the approval of new drug applications and clinical trials by various companies, indicating a dynamic and evolving market landscape [16][17].

5月9日，博时健康成长双周定期可赎回混合A（009468）下跌0.01%，最新净值0.85元，连续3个交易日 下跌，区间累计跌幅1.25%。 据了解，博时健康成长双周定期可赎回混合A成立于2020年6月，基金规模3.62亿元，成立来累计收益 率-14.96%。从持有人结构来看，截至2024年末，博时健康成长双周定期可赎回混合A的基金机构持有 0.11亿份，占总份额的2.35%，个人投资者持有4.44亿份，占总份额的97.65%。 公开信息显示，现任基金经理陈西铭女士:中国国籍,硕士,2016-至今博时基金管理有限公司/历任研究 员、高级研究员兼基金经理助理、资深研究员兼基金经理助理。现任博时健康成长主题双周定期可赎回 混合型证券投资基金的基金经理。2021年12月9日任博时健康成长主题双周定期可赎回混合型证券投资 基金基金经理。2023年3月14日任博时医疗保健行业混合型证券投资基金基金经理。现任博时健康生活 混合型证券投资基金的基金经理。 截止2025年3月31日，博时健康成长双周定期可赎回混合A前十持仓占比合计34.13%，分别为：泽璟制 药-U（7.08%）、科伦博泰生（4.68%）、科伦药业（4.00 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of May 9, 2025, the latest net value of the fund is 2.5040 yuan, with a growth of 0.72%. The fund's return over the past month is 5.17%, ranking 504 out of 783 in its category; over the past three months, the return is 9.06%, ranking 88 out of 778; and year-to-date, the return is 9.87%, ranking 103 out of 773 [1] - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Mindray Medical (2.80%) [1] Group 2 - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014, while Ding Yang joined the company in 2017 and currently serves as a fund manager [2]

证券代码：300765 证券简称：新诺威 公告编号：2025-047 石药创新制药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召开第 六届董事会第二十二次会议、第六届监事会第十七次会议，于 2025 年 4 月 15 日 召开 2024 年年度股东大会，会议审议并通过了《关于使用部分闲置募集资金及 自有资金进行现金管理的议案》。在不影响募集资金投资项目建设和公司正常经 营的情况下，公司及子公司使用不超过人民币 8.00 亿元（含本数）额度的闲置募 集资金及不超过人民币 8.00 亿元（含本数）的自有资金进行现金管理，投资安全 性高、流动性好的保本型产品（包括结构性存款、大额存单等），使用期限自股 东大会审议通过之日起 12 个月内有效。在上述额度及决议有效期内，业务可循 环滚动开展。具体内容详见巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于使用部分闲置募集资金及自有资金进行现金管理的公告》 ...

截至2025年5月9日 10:02，中证主要消费指数(000932)上涨0.21%，成分股新诺威(300765)上涨2.41%，贝泰妮(300957)上涨1.73%，养元饮品(603156)上涨 1.62%，今世缘(603369)上涨1.59%，珀莱雅(603605)上涨1.57%。主要消费ETF(159672)上涨0.13%， 冲击5连涨。最新价报0.78元。 海通国际指出，近期资本市场热点纷呈：一是国内货币政策和财政政策进一步放松；二是贸易冲突由加码转向缓和；三是印度与巴基斯坦冲突爆发，中式武 器表现亮眼催化军工板块。另一方面必需消费板块需求增长缓慢，短期缺少基本面催化剂，政策面强刺激预期减弱，资金面也有被吸出的风险。但是从长期 看，中国资产重估逻辑依旧，经历贸易冲突和军备检验后更显价值。目前时点，我们的推荐顺序和组合不变，建议关注乳业（供给收缩先于需求改善）、软 饮料（稳增长前提下的高股息）和白酒（大资金流入的必配行业）。 主要消费ETF紧密跟踪中证主要消费指数，为反映中证800指数样本中不同行业公司证券的整体表现，为投资者提供分析工具，将中证800指数样本按中证行 业分类分为11个一级行业与35个二级 ...

Group 1 - In the first four months of the year, 555 out of 999 comparable ordinary stock funds achieved positive performance, accounting for 55% of the total, with 25 funds rising over 20% [1] - The top-performing funds include Ping An Advanced Manufacturing Theme Stock A and C, with returns of 52.59% and 52.29% respectively [1] - The top ten holdings of the Ping An Advanced Manufacturing fund include Hengli Hydraulic, Zhejiang Rongtai, and Huashu High-Tech [1] Group 2 - The healthcare sector saw significant gains, with funds like Bank of China Health A and C, and Huaan Pharmaceutical Biotech A and C achieving returns of 41.72%, 41.53%, 40.70%, and 40.52% respectively [2] - The top holdings of the Bank of China Health fund include Heng Rui Medicine and Xin Nuo Wei [2] - The management of the Bank of China Health fund transitioned to Wang Fangzhou and Zheng Ning in March [2] Group 3 - The worst-performing fund was Guolian An Technology Power Stock, which declined by 17.45% [3] - This fund's top holdings include Hengxuan Technology and Ruixin Micro [3] - The fund is managed by veteran Pan Ming, who has extensive experience in investment management [3] Group 4 - Several funds, including Caitong Integrated Circuit Industry Stock C and GF High-end Manufacturing Stock C, suffered declines of 15.02% to 14.70% due to poor performance in the technology and new energy sectors [4] - The performance of these funds reflects broader challenges in the technology and manufacturing sectors [4] Group 5 - The top 100 stock funds by performance in the first four months show a diverse range of returns, with Ping An Advanced Manufacturing leading and several healthcare funds also performing well [5][6] - The data indicates a strong interest in healthcare and advanced manufacturing sectors among investors [5][6]

证券代码：300765 证券简称：新诺威 公告编号：2025-046 石药创新制药股份有限公司 关于控股股东增持公司股份计划实施完成的公告 控股股东石药集团恩必普药业有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 1、石药创新制药股份有限公司（以下简称"公司"）于 2024 年 11 月 8 日 披露《关于控股股东增持公司股份计划的公告》（公告编号：2024-102），公司 控股股东石药集团恩必普药业有限公司（以下简称"恩必普药业"）计划自 2024 年 11 月 8 日（含本日）起 6 个月内，择机增持公司股份，增持金额不低于人民 币 10,000.00 万元，不超过人民币 12,000.00 万元。 2、增持计划的进展情况：截至本公告披露日，恩必普药业的增持计划已实 施完成。自 2024 年 11 月 8 日至 2025 年 5 月 7 日，恩必普药业通过深圳证券交 易所交易系统以集中竞价方式累计增持公司股份 3,313,900 股，占公司总股本的 0.24%（已剔除最新披露的公司 ...

关于 石药创新制药股份有限公司 控股股东增持公司股份 之 法律意见书 中国北京东城区金宝街 89 号金宝大厦 11 层 邮编：100005 11F, Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing 100005, P.R.C. 电话(Tel)： (86-10) 6652 3388 传真(Fax)：（86-10）6652 3399 网址（Website）： www.junzejun.com 电子信箱（E-mail）：jzj@junzejun.com 释 义 在本法律意见书中，除非文义另有所指，下列左栏中的术语或简称对应右栏 中的含义或全称： | 公司、新诺威 | 指 | 石药创新制药股份有限公司 | | --- | --- | --- | | 增持人、控股股东、恩必 | 指 | 石药集团恩必普药业有限公司，现为公司控股股东 | | 普药业 | | | | 本次增持 | 指 | 恩必普药业拟自 2024 年 11 月 8 日（含本日）起 6 个月内， 万元， | | | | 择机增持公司股份，增持金额不低于人民币 10,000.00 | | ...

Core Viewpoint - New Nuo Wei (300765.SZ) announced the termination of its application for the acquisition of Shiyao Chuangxin Pharmaceutical Co., Ltd. and the associated fundraising, ending a 15-month effort for a significant restructuring deal worth 7.6 billion yuan [2][3]. Group 1: Termination of Acquisition - The termination was due to changes in the pharmaceutical industry and capital market environment since the initial planning of the restructuring, leading to a decision made in the interest of long-term shareholder benefits [2][3]. - The market reacted rationally to the termination, influenced by factors such as stock price fluctuations, increasing performance burdens, and declining acquisition targets [2][3]. Group 2: Financial Performance and Challenges - New Nuo Wei's revenue and profit have been declining, with a 21.98% year-on-year decrease in revenue to 1.981 billion yuan and an 87.63% drop in net profit to 54 million yuan in 2024 [8]. - The company's core revenue from functional foods and raw materials fell by 24.90% to 1.84 billion yuan, while the biopharmaceutical sector contributed only 87.8 million yuan, despite a 153.0% increase [10]. Group 3: Acquisition Details and Valuation - The acquisition target, Shiyao Baike, has a core product, Jinyouli, which is facing growth challenges, with a significant reliance on a single product and limited growth potential [4][7]. - The valuation for Shiyao Baike was set at 7.622 billion yuan, representing a 78.25% premium over its book value of 4.276 billion yuan, raising concerns about the high price for low-growth assets [6][7]. Group 4: R&D and Future Prospects - New Nuo Wei's R&D expenses increased by 25.44% to 842 million yuan in 2024, primarily due to the inclusion of Shiji Biological's R&D costs, indicating a significant financial burden [10][11]. - The company is under pressure from negative cash flows, with net cash flow from operating activities at -1.235 billion yuan in 2024 and -87 million yuan in the first quarter of 2025 [12][13].